SCHEMBL11943953

SCHEMBL11943953

CC(C)S(=O)(=O)N1CCN(c2cnn(-c3ccccn3)c(=O)c2OC2CCCCC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ GRM7 Q14831 7/20 0.38
▸ DCTPP1 Q9H773 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ GRM1 Q13255 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ MMP1 P03956 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ CACNB4 O00305 1/20 0.36
▸ CACNA1A O00555 1/20 0.36
▸ CACNA1G O43497 1/20 0.36
▸ CACNG3 O60359 1/20 0.36
▸ CACNA1F O60840 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945070 0.90 CA12 (0.41) CA12CA1CA2CA9ALDH1A1
SCHEMBL11944001 0.89 ALDH1A1 (0.48) CA12CA1CA2CA9ALDH1A1
SCHEMBL11944522 0.89 CA12 (0.39) CA12CA1CA2CA9ALDH1A1
SCHEMBL11946097 0.88 ALDH1A1 (0.35) CA12CA1CA2CA9ALDH1A1
SCHEMBL11945061 0.87 ALDH1A1 (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL11944312 0.87 CA12 (0.39) CA12CA1CA2CA9ALDH1A1
SCHEMBL11944101 0.86 ALDH1A1 (0.51) ALDH1A1MAPTDCTPP1KMT2ACACNB4
SCHEMBL11945074 0.84 MAPT (0.41) CA12CA1CA2CA9ALDH1A1
SCHEMBL11946104 0.84 ALDH1A1 (0.33) ALDH1A1MAPTDCTPP1CACNB4CACNA1A
SCHEMBL11944442 0.84 CACNB4 (0.38) ALDH1A1MAPTDCTPP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA CA12 4603/4885CA1 4563/4885CA2 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback